Brief: Nrx Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy And Safety Of Intravenous Ketamine For The Treatment Of Suicidal Bipolar Depression
15/09/2023 12:31
NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS ANNOUNCES DATA SHARING AGREEMENT
DEMONSTRATING EFFICACY AND SAFETY OF INTRAVENOUS KETAMINE FOR
THE TREATMENT OF SUICIDAL BIPOLAR DEPRESSION
* NRX PHARMACEUTICALS INC - PLANS TO PRESENT DATA TO FDA
WITH A
GOAL OF IDENTIFYING A PATH TO AN NDA
* NRX PHARMACEUTICALS INC - KETAMINE, AN NMDA BLOCKER, WAS
HIGHLY
EFFECTIVE IN BIPOLAR SUBGROUP (P<0.001)
Source text for Eikon: ID:nPn1rPbgHa
Further company coverage: NRXP.O
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview